Evaluating Neostigmine Effect on Reducing Gastric Residual Volume as Compared With Metoclopramide and Ondansetron

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (136 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-10-17. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 25 (lowers risk) · Who can join
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 140 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Blinding: triple (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 13.3% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: prevention (lowers risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 21347 (raises risk) · Drug's FDA history
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: hourscontrolledicucareventilated
  Phrases that lowered it: effectgastricpatientsevaluatemm
• Drug's FAERS reports marked serious: 82.2% (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients NCT05496179 · started 2022 · scored riskier than 14% of active trials completed
• Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients NCT01117376 · started 2010 · scored riskier than 30% of active trials terminated
• A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance NCT01953081 · started 2014 · scored riskier than 80% of active trials completed
• The Effect of Intravenous Erythromycin on Gastric Emptying in Non-fasted Patients Before Emergency Total Anesthesia NCT00827216 · started 2009 · scored riskier than 59% of active trials completed
• Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial NCT02784392 · started 2016 · scored riskier than 35% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.